NDAORALTABLET
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
8/100
Clinical Trials
20
Mechanism of Action
Sodium-Glucose Transporter 2 Inhibitors
Pharmacologic Class:
Sodium-Glucose Cotransporter 2 Inhibitor
Clinical Trials (5)
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Started Oct 2024
Sotagliflozin Multiple-dose Study in Healthy Chinese Subjects
Started Apr 2019
24 enrolled
Diabetes Mellitus
A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions
Started Jan 2019
66 enrolled
Type 2 Diabetes MellitusHealthy Subjects
Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects
Started Jan 2019
6 enrolled
Type 2 Diabetes MellitusHealthy Subjects
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea
Started Nov 2018
377 enrolled
Type 2 Diabetes Mellitus
Loss of Exclusivity
LOE Date
Oct 7, 2030
55 months away
Patent Expiry
Oct 7, 2030
Exclusivity Expiry
May 26, 2028